APLS Apellis grabbed the most analyst attention this week. The $5.2B biotech soared 61% year to date pulling coverage as the stock hit 87 RSI. Analysts adjusted targets as momentum built despite 26% short interest.
CNTA Centessa drew heavy revisions after surging 59% in 2026. The $6.1B drug developer held 79 ORTEX score signaling quality metrics. Analysts reset price targets following the rally as SI stayed light at 7.7%.
NKE Nike absorbed fresh downgrades as the $53B athletic giant crashed 31% year to date. Analysts slashed targets with consensus showing 49% upside potential from current levels. RSI plunged to 20 indicating extreme oversold territory.
MSFT Microsoft saw analyst reassessments after dropping 24% in 2026. The $2.8T software leader held 87 ORTEX score yet faced 57% upside to target. Revisions reflected concern over valuation compression despite quality fundamentals.
Phreesia collapsed 51% year to date yet analysts maintained 118% upside targets. The healthcare tech name grabbed attention as RSI hit 24 suggesting potential reversal opportunity. Biotech momentum names dominated positive revisions while mega-cap tech absorbed caution.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
